Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: real-world evidence using a nationwide database.

"Competing interests: MS has speaking contracts, clinical trial contracts and/or consults with AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Swedish Orphan Biovitrum and UCB. IO has speaking contracts and/or consults with AbbVie, Almirall, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Servier. SJ has speaking contracts, clinical trial contracts and/or consults AbbVie, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Celgene, Egis, Eli Lilly, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Samsung Bioepis and UCB. BB has speaking contracts, clinical trial contracts and/or consults with AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz and UCB. MS is the author acting as guarantor."

"Funding: The study was supported by Polish Society for Rheumatology within the BIOTAPOL project ‘BIOlogical Therapies Access in rheumatic diseases in POLand’."